Andrea Steck
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 122 | 2026 | 3842 | 9.070 |
Why?
| | Autoantibodies | 78 | 2026 | 1497 | 7.530 |
Why?
| | Islets of Langerhans | 44 | 2026 | 832 | 4.570 |
Why?
| | Autoimmunity | 36 | 2025 | 924 | 2.960 |
Why?
| | C-Peptide | 17 | 2026 | 186 | 2.750 |
Why?
| | Genetic Predisposition to Disease | 37 | 2026 | 2359 | 2.560 |
Why?
| | Insulin Antibodies | 11 | 2022 | 103 | 2.290 |
Why?
| | Polymorphism, Single Nucleotide | 27 | 2026 | 2143 | 2.020 |
Why?
| | Disease Progression | 38 | 2026 | 2840 | 1.690 |
Why?
| | Insulin | 25 | 2026 | 2501 | 1.690 |
Why?
| | Blood Glucose | 16 | 2026 | 2312 | 1.630 |
Why?
| | Glutamate Decarboxylase | 17 | 2022 | 165 | 1.610 |
Why?
| | Child | 89 | 2026 | 22537 | 1.400 |
Why?
| | Prediabetic State | 5 | 2026 | 243 | 1.390 |
Why?
| | Hyperglycemia | 3 | 2024 | 374 | 1.310 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 7 | 2019 | 48 | 1.300 |
Why?
| | Child, Preschool | 59 | 2026 | 11774 | 1.290 |
Why?
| | Diabetes Mellitus, Type 2 | 13 | 2026 | 2516 | 1.260 |
Why?
| | Genotype | 24 | 2026 | 1833 | 1.260 |
Why?
| | HLA-DR Antigens | 8 | 2016 | 220 | 1.240 |
Why?
| | Adolescent | 71 | 2026 | 22281 | 1.170 |
Why?
| | HLA-DQ Antigens | 9 | 2024 | 173 | 1.140 |
Why?
| | HLA-DR3 Antigen | 9 | 2024 | 76 | 1.090 |
Why?
| | Haplotypes | 10 | 2026 | 490 | 0.950 |
Why?
| | Diabetic Ketoacidosis | 4 | 2024 | 209 | 0.930 |
Why?
| | Male | 93 | 2026 | 72035 | 0.880 |
Why?
| | Infant | 35 | 2024 | 10022 | 0.880 |
Why?
| | Blood Glucose Self-Monitoring | 7 | 2025 | 699 | 0.870 |
Why?
| | Health Resources | 1 | 2026 | 129 | 0.870 |
Why?
| | Humans | 138 | 2026 | 144261 | 0.860 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2017 | 54 | 0.840 |
Why?
| | Female | 93 | 2026 | 77976 | 0.840 |
Why?
| | Insulin-Secreting Cells | 12 | 2026 | 387 | 0.820 |
Why?
| | HLA Antigens | 6 | 2026 | 225 | 0.810 |
Why?
| | Young Adult | 40 | 2026 | 13990 | 0.800 |
Why?
| | Precision Medicine | 2 | 2025 | 456 | 0.800 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2017 | 427 | 0.800 |
Why?
| | Internal Medicine | 1 | 2026 | 280 | 0.770 |
Why?
| | Genetic Testing | 7 | 2025 | 478 | 0.750 |
Why?
| | Mass Screening | 11 | 2025 | 1332 | 0.730 |
Why?
| | Zinc Transporter 8 | 7 | 2021 | 70 | 0.720 |
Why?
| | Hypoglycemic Agents | 7 | 2026 | 1379 | 0.720 |
Why?
| | Risk Factors | 33 | 2026 | 10699 | 0.690 |
Why?
| | Glucose Tolerance Test | 10 | 2026 | 360 | 0.680 |
Why?
| | HLA-D Antigens | 2 | 2019 | 30 | 0.670 |
Why?
| | Age of Onset | 12 | 2021 | 536 | 0.650 |
Why?
| | HLA-DR4 Antigen | 6 | 2024 | 74 | 0.640 |
Why?
| | Prospective Studies | 24 | 2026 | 7970 | 0.630 |
Why?
| | Diabetes Mellitus | 3 | 2025 | 1092 | 0.610 |
Why?
| | C-Reactive Protein | 2 | 2018 | 416 | 0.570 |
Why?
| | Family | 5 | 2025 | 679 | 0.550 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2017 | 14 | 0.530 |
Why?
| | Celiac Disease | 4 | 2022 | 308 | 0.490 |
Why?
| | Sensitivity and Specificity | 9 | 2022 | 1983 | 0.470 |
Why?
| | Adult | 39 | 2026 | 40262 | 0.460 |
Why?
| | DNA Methylation | 5 | 2024 | 681 | 0.440 |
Why?
| | Case-Control Studies | 12 | 2021 | 3592 | 0.440 |
Why?
| | Models, Genetic | 1 | 2017 | 535 | 0.430 |
Why?
| | Proinsulin | 2 | 2020 | 51 | 0.420 |
Why?
| | Polymorphism, Genetic | 5 | 2019 | 612 | 0.400 |
Why?
| | Follow-Up Studies | 11 | 2021 | 5389 | 0.380 |
Why?
| | HLA-DQ beta-Chains | 4 | 2019 | 57 | 0.380 |
Why?
| | Luminescent Measurements | 4 | 2021 | 76 | 0.380 |
Why?
| | Transcription Factor 7-Like 2 Protein | 5 | 2021 | 26 | 0.370 |
Why?
| | Luminescence | 4 | 2016 | 39 | 0.370 |
Why?
| | Twins, Monozygotic | 5 | 2025 | 134 | 0.360 |
Why?
| | Cation Transport Proteins | 4 | 2017 | 118 | 0.360 |
Why?
| | Quality Improvement | 2 | 2017 | 1285 | 0.340 |
Why?
| | Risk | 6 | 2019 | 909 | 0.300 |
Why?
| | HLA-DQ alpha-Chains | 3 | 2019 | 16 | 0.290 |
Why?
| | Family Health | 4 | 2017 | 191 | 0.280 |
Why?
| | Antigens, CD | 2 | 2009 | 555 | 0.280 |
Why?
| | Longitudinal Studies | 7 | 2024 | 2926 | 0.270 |
Why?
| | Risk Assessment | 6 | 2025 | 3637 | 0.270 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 109 | 0.270 |
Why?
| | Predictive Value of Tests | 7 | 2019 | 2111 | 0.270 |
Why?
| | Cohort Studies | 11 | 2021 | 5935 | 0.270 |
Why?
| | Transglutaminases | 2 | 2021 | 159 | 0.270 |
Why?
| | Major Histocompatibility Complex | 4 | 2017 | 229 | 0.270 |
Why?
| | Colorado | 6 | 2024 | 4562 | 0.260 |
Why?
| | Pancreas | 3 | 2024 | 341 | 0.250 |
Why?
| | CTLA-4 Antigen | 3 | 2017 | 104 | 0.250 |
Why?
| | Alleles | 4 | 2021 | 878 | 0.240 |
Why?
| | Age Factors | 6 | 2022 | 3313 | 0.240 |
Why?
| | Middle Aged | 18 | 2026 | 35762 | 0.230 |
Why?
| | Interrupted Time Series Analysis | 1 | 2026 | 74 | 0.230 |
Why?
| | Diabetes Complications | 2 | 2018 | 220 | 0.230 |
Why?
| | Autoantigens | 2 | 2021 | 429 | 0.230 |
Why?
| | Autoimmune Diseases | 3 | 2017 | 463 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2006 | 167 | 0.220 |
Why?
| | Prognosis | 7 | 2021 | 4278 | 0.220 |
Why?
| | Twins, Dizygotic | 3 | 2025 | 109 | 0.220 |
Why?
| | Plasmids | 1 | 2026 | 379 | 0.220 |
Why?
| | Infant, Newborn | 8 | 2025 | 6424 | 0.200 |
Why?
| | Gene Frequency | 6 | 2020 | 481 | 0.200 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1128 | 0.190 |
Why?
| | Neurology | 1 | 2024 | 110 | 0.190 |
Why?
| | Hydroxychloroquine | 1 | 2023 | 63 | 0.190 |
Why?
| | Biomarkers | 6 | 2021 | 4254 | 0.190 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1322 | 0.190 |
Why?
| | Glucokinase | 2 | 2013 | 15 | 0.190 |
Why?
| | Phenotype | 3 | 2024 | 3157 | 0.180 |
Why?
| | Radioimmunoassay | 3 | 2017 | 165 | 0.180 |
Why?
| | Prevalence | 3 | 2024 | 2815 | 0.180 |
Why?
| | Chromosome Mapping | 2 | 2021 | 509 | 0.170 |
Why?
| | Hospital Mortality | 1 | 2026 | 1027 | 0.170 |
Why?
| | Early Diagnosis | 3 | 2020 | 247 | 0.170 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1406 | 0.170 |
Why?
| | Seroconversion | 1 | 2021 | 49 | 0.170 |
Why?
| | Area Under Curve | 2 | 2020 | 329 | 0.160 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 153 | 0.160 |
Why?
| | Length of Stay | 1 | 2026 | 1335 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 886 | 0.160 |
Why?
| | Iodide Peroxidase | 2 | 2020 | 34 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 211 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 985 | 0.150 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1982 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2022 | 668 | 0.140 |
Why?
| | Down-Regulation | 1 | 2021 | 627 | 0.140 |
Why?
| | Incidence | 4 | 2022 | 2870 | 0.140 |
Why?
| | Insulin Resistance | 3 | 2021 | 1232 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1533 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 964 | 0.130 |
Why?
| | Genetic Association Studies | 4 | 2025 | 372 | 0.130 |
Why?
| | Receptors, CCR7 | 1 | 2017 | 31 | 0.130 |
Why?
| | Discriminant Analysis | 1 | 2017 | 36 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2021 | 784 | 0.130 |
Why?
| | Fasting | 2 | 2018 | 276 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 612 | 0.130 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 62 | 0.130 |
Why?
| | Blood Specimen Collection | 1 | 2017 | 38 | 0.130 |
Why?
| | Immunoglobulin M | 2 | 2021 | 284 | 0.130 |
Why?
| | Health Care Costs | 1 | 2020 | 421 | 0.120 |
Why?
| | Transcription Factors | 2 | 2017 | 1739 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 643 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 615 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 982 | 0.120 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 833 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1217 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 768 | 0.110 |
Why?
| | Hypoglycemia | 2 | 2020 | 477 | 0.110 |
Why?
| | Iron-Binding Proteins | 1 | 2015 | 43 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 104 | 0.110 |
Why?
| | RNA, Long Noncoding | 1 | 2017 | 177 | 0.110 |
Why?
| | Peptides | 1 | 2021 | 995 | 0.110 |
Why?
| | Trans-Activators | 1 | 2017 | 405 | 0.110 |
Why?
| | Dried Blood Spot Testing | 1 | 2015 | 126 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 459 | 0.100 |
Why?
| | Aged | 6 | 2026 | 25850 | 0.100 |
Why?
| | Self Care | 1 | 2017 | 388 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2017 | 437 | 0.100 |
Why?
| | Europe | 3 | 2024 | 412 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2013 | 15 | 0.100 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2013 | 7 | 0.100 |
Why?
| | Glucose | 3 | 2023 | 1046 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 21 | 0.100 |
Why?
| | Population Surveillance | 1 | 2017 | 483 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1519 | 0.100 |
Why?
| | Genetic Linkage | 2 | 2011 | 273 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 97 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 84 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3857 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2026 | 2025 | 0.090 |
Why?
| | United Kingdom | 3 | 2018 | 336 | 0.090 |
Why?
| | Proteins | 1 | 2017 | 1021 | 0.080 |
Why?
| | Siblings | 2 | 2018 | 195 | 0.080 |
Why?
| | Stroke | 2 | 2010 | 1254 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1054 | 0.080 |
Why?
| | Penetrance | 1 | 2011 | 29 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1255 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2026 | 0.080 |
Why?
| | Atrial Natriuretic Factor | 1 | 2010 | 56 | 0.080 |
Why?
| | Skin | 1 | 2015 | 754 | 0.080 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 172 | 0.080 |
Why?
| | Gene Expression | 2 | 2021 | 1487 | 0.080 |
Why?
| | Glycopeptides | 1 | 2010 | 44 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 399 | 0.080 |
Why?
| | Genetic Markers | 1 | 2011 | 331 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1497 | 0.080 |
Why?
| | Inflammation | 2 | 2020 | 2877 | 0.070 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 202 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2011 | 364 | 0.070 |
Why?
| | TCF Transcription Factors | 1 | 2008 | 19 | 0.070 |
Why?
| | Nuclear Family | 1 | 2009 | 52 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 758 | 0.070 |
Why?
| | Obesity | 2 | 2019 | 3057 | 0.070 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 97 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 90 | 0.070 |
Why?
| | Metabolomics | 2 | 2025 | 726 | 0.070 |
Why?
| | Mutation | 2 | 2015 | 4085 | 0.060 |
Why?
| | Gene-Environment Interaction | 2 | 2020 | 180 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 44 | 0.060 |
Why?
| | CpG Islands | 2 | 2016 | 165 | 0.060 |
Why?
| | Finland | 1 | 2025 | 79 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 573 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2424 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Biosensing Techniques | 1 | 2007 | 139 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 684 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3403 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 77 | 0.060 |
Why?
| | Cell Death | 2 | 2019 | 383 | 0.060 |
Why?
| | Protein Precursors | 1 | 2026 | 136 | 0.060 |
Why?
| | Environment | 2 | 2018 | 305 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 177 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 176 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2026 | 437 | 0.050 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2005 | 206 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 144 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2021 | 780 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2010 | 789 | 0.050 |
Why?
| | Animals | 4 | 2022 | 38030 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2026 | 309 | 0.050 |
Why?
| | Dysbiosis | 1 | 2025 | 187 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 379 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 219 | 0.050 |
Why?
| | Administration, Oral | 1 | 2026 | 847 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 519 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2023 | 1559 | 0.050 |
Why?
| | Parents | 2 | 2023 | 1401 | 0.050 |
Why?
| | Metabolome | 1 | 2025 | 384 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 7155 | 0.040 |
Why?
| | Feasibility Studies | 2 | 2017 | 1087 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 73 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | China | 1 | 2021 | 269 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 53 | 0.040 |
Why?
| | Latent Autoimmune Diabetes in Adults | 1 | 2020 | 3 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 331 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 103 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2021 | 214 | 0.040 |
Why?
| | Perception | 1 | 2023 | 377 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 824 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 55 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 158 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 59 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2021 | 154 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 154 | 0.040 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 168 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 117 | 0.040 |
Why?
| | Linkage Disequilibrium | 2 | 2011 | 246 | 0.040 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 84 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 729 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2026 | 11643 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 218 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 549 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 113 | 0.040 |
Why?
| | Butyrates | 1 | 2019 | 67 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 242 | 0.040 |
Why?
| | Fibrinogen | 1 | 2019 | 176 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Mothers | 1 | 2005 | 774 | 0.030 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2018 | 181 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 2019 | 179 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 431 | 0.030 |
Why?
| | Pennsylvania | 1 | 2018 | 136 | 0.030 |
Why?
| | Sweden | 1 | 2018 | 111 | 0.030 |
Why?
| | Germany | 1 | 2018 | 138 | 0.030 |
Why?
| | Diseases in Twins | 1 | 2018 | 115 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1044 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 374 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2019 | 346 | 0.030 |
Why?
| | Twins | 1 | 2018 | 156 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 455 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 623 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 105 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 893 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2022 | 846 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1104 | 0.030 |
Why?
| | Capillaries | 1 | 2017 | 124 | 0.030 |
Why?
| | Automation, Laboratory | 1 | 2015 | 7 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 187 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 312 | 0.030 |
Why?
| | Thyroid Gland | 1 | 2015 | 88 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2013 | 8243 | 0.030 |
Why?
| | North America | 1 | 2015 | 310 | 0.030 |
Why?
| | Fetal Blood | 1 | 2016 | 342 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5813 | 0.020 |
Why?
| | Overweight | 1 | 2018 | 606 | 0.020 |
Why?
| | Patient Preference | 1 | 2015 | 221 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2025 | 17009 | 0.020 |
Why?
| | Polyneuropathies | 1 | 2013 | 57 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 555 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1129 | 0.020 |
Why?
| | Genome | 1 | 2014 | 306 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 405 | 0.020 |
Why?
| | Rituximab | 1 | 2013 | 209 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1075 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1820 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1091 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 33 | 0.020 |
Why?
| | Genetic Loci | 1 | 2011 | 261 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 878 | 0.020 |
Why?
| | Exercise | 1 | 2022 | 2193 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2010 | 121 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 250 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2009 | 52 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 704 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 2009 | 56 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2061 | 0.020 |
Why?
| | Hyperinsulinism | 1 | 2010 | 113 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 28 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 43 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 19 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 199 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2009 | 245 | 0.020 |
Why?
| | Telomere | 1 | 2011 | 287 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2917 | 0.020 |
Why?
| | Heterozygote | 1 | 2009 | 315 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2187 | 0.020 |
Why?
| | Pedigree | 1 | 2009 | 513 | 0.020 |
Why?
| | DNA | 1 | 2014 | 1460 | 0.020 |
Why?
| | United States | 2 | 2015 | 15876 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2929 | 0.020 |
Why?
| | Brain Ischemia | 1 | 2010 | 358 | 0.020 |
Why?
| | Genome, Human | 1 | 2009 | 422 | 0.020 |
Why?
| | Tissue Donors | 1 | 2010 | 424 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2104 | 0.010 |
Why?
| | Mice | 1 | 2022 | 18329 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2420 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1782 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2382 | 0.010 |
Why?
|
|
Steck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|